As reported on April 25, medical device company Masimo encountered yet another setback in its ongoing patent dispute concerning the blood oxygen detection technology used in the Apple Watch. The most recent filing from the U.S. District Court for the District of Columbia indicates that Masimo’s lawsuit against the U.S. International Trade Commission (USITC) will be concluded with a 'dismissal with prejudice.' This outcome means that Masimo cannot bring forth the same claim again in the same court.

The origins of this dispute trace back to 2020, when Masimo initially accused Apple of infringing upon its patents through the incorporation of blood oxygen detection technology in the Apple Watch. Subsequently, Masimo filed multiple lawsuits. Although Masimo secured a favorable ruling from a federal jury in November 2025, which awarded the company $634 million in damages, Apple has since filed an appeal. The dismissal of this particular lawsuit represents a notable setback for Masimo in its legal efforts to halt the sale of the Apple Watch’s blood oxygen feature.